High-throughput sequencing has significantly contributed to revealing the molecular underpinnings of B-cell lymphomagenesis and disease progression. It is now a widely accepted concept that the diversity of clinical responses to front-line therapy and the development of relapsed/refractory disease are in part explained by 'inter-patient' genetic heterogeneity measurable by individual sets of somatic gene alterations in tumor genomes. Moreover, extensive 'intra-tumor' heterogeneity on the genotypic and phenotypic levels is the product of ongoing tumor evolution and adaptation to various selective pressures during cancer initiation, progression, and therapeutic intervention. As the management of disease progression remains one of the most significant clinical challenges, it is becoming increasingly important to delineate how B-cell lymphomas evolve over time and to develop progression-related biomarker assays. Toward this goal, recent investigations have moved from studying lymphoma biology at initial diagnosis to doing so at multiple time points during the disease course. Profiling progressed tumors, and in particular paired biopsies at initial diagnosis and disease progression of the same patients, has led to novel insights into clonal tumor evolution and tumor microenvironment dynamics. This review discusses the latest findings on genomic alterations and microenvironment biology associated with relapsed/refractory B-cell lymphomas, with a particular emphasis on alterations that are acquired or become more prevalent at disease progression. We also describe overarching tumor evolution patterns, and highlight emerging precision medicine methodologies that can aid in an improved understanding and management of relapsed/refractory disease.
Introduction
B-cell lymphomas comprise a group of neoplasms arising from developing or mature B cells [1] . These cancers are characterized by notable heterogeneity in disease course, ranging from aggressive or treatment-resistant disease to indolent disease requiring no need for immediate therapeutic action. Despite the improvements in the standard of care for B-cell lymphoma patients, with the introduction of immuno-chemotherapies, a proportion of patients still suffer disease progression and ultimately succumb to the disease [2] . This is partially due to a lack of reliable prognostic and predictive biomarkers to assign patients to suitable treatment regimens. The development of such biomarkers has been hampered by an incomplete understanding of the biology and evolutionary patterns of treatment-resistant disease, owing in part to limited availability of relapse samples for study.
The advent of high-throughput sequencing (HTS) has led to novel insights into the molecular underpinnings of B-cell lymphomagenesis [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Sequence analyses of these lymphomas at initial diagnosis have revealed a high degree of inter-patient tumor heterogeneity and have been comprehensively reviewed elsewhere [13] [14] [15] [16] . Recently, there has been a shift in focus from studying diagnostic biopsies alone to pairing such analyses with specimens obtained at the time point of disease progression. This has allowed for a greater understanding of the 'relapse genomics' in lymphoma. These efforts have also presented evidence of branched tumor evolution during disease progression, wherein tumors consist of multiple distinct clones that share a common ancestor but differ in alterations that occur later in the evolutionary progression of the tumor. In particular, the myriad of acquired genomic alterations provide the substrate upon which branched evolutionary processes operate, and in turn result in the extensive inter-and intra-tumor heterogeneity observed in lymphomas.
In this review, we focus on discussing the molecular underpinnings associated with relapsed/refractory lymphoma. As diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the most common lymphoma subtypes, we will be focusing on these two diseases as paradigms for studies in less common B-cell lymphomas. We emphasize the importance of viewing disease progression in the context of an evolutionary framework. Finally, we highlight emerging precision medicine approaches and concepts to develop biomarker assays at disease progression, with an emphasis on classical Hodgkin lymphoma (CHL).
Recurrent molecular themes associated with lymphoma disease progression
Recently, several efforts have explored the molecular underpinnings of relapse/refractory lymphomas. Study designs fall into three categories: (1) Comparisons of primary specimens of patients who relapse or whose treatments fail versus those who achieve long-term remission ( Figure 1A ). This approach reveals biomarkers that predict or pre-empt the occurrence of disease progression; (2) Profiles of relapse biopsies compared with unselected primary biopsies to characterize specific characteristics of relapse/refractory disease ( Figure 1B ). This study design reveals genes and pathways that are dysregulated, and paves the way to a clearer understanding of the pathogenesis of relapse disease; (3) Direct comparisons between paired primary and relapse samples on a patient-centric level ( Figure 1C ). The latter approach allows for the identification of alterations that reside in cell populations of an expanded clone that might be therapeutically targetable. Results of these three study designs are discussed in the following section and are summarized in Figure 2 . To balance brevity and clarity, we will primarily focus on studies that have investigated selected cohorts of relapse/refractory patients, with a particular emphasis on comparisons of serial specimens. Such studies provide the most reliable association of genetic lesions with disease progression. An important caveat of these analyses is that in some instances they are limited by the quality of samples (i.e. formalin-fixed, paraffin-embedded) and profiling technology (i.e. targeted interrogation of the genome), and thus may not reflect the full complement of genetic heterogeneity involved in disease initiation and progression. Moreover, recent studies have highlighted the large extent of heterogeneity in primary specimens and have implied that the extent of heterogeneity in relapse specimens, which could be equal to or greater than that of primary specimens, has yet to be revealed.
Common alterations in relapse/refractory DLBCL and transformed FL
Clinical outcomes of DLBCL patients have drastically improved due to the addition of rituximab to the previous standard-of-care polychemotherapy (R-CHOP) [17] . Despite this improvement, approximately 30-40% of patients still develop relapse/refractory DLBCL (rrDLBCL), with the majority of these patients eventually succumbing to the disease [18] . Therefore, understanding the mechanisms underlying primary treatment failure and driving disease progression of rrDLBCL is paramount. While the genomic landscape of primary DLBCL has been thoroughly characterized [3, 4, 6, 9, 19] , studies profiling how this landscape shifts for relapse/refractory disease remains relatively understudied.
Follicular lymphoma (FL) is an indolent B-cell malignancy of germinal-center B-cell origin with a relatively long overall survival rate [20] [21] [22] . It is characterized by a hallmark t(14;18) translocation that occurs in 85-90% of all patients and is considered to be one of the earliest genomic alterations to occur in the oncogenic cascade leading to the initiation of FL [23] . However, 10-15% of FL patients do not carry this alteration and healthy individuals may also have B cells harboring the translocation. This suggests that the translocation alone is neither necessary nor sufficient for lymphomagenesis [24, 25] . The disease is considered essentially incurable, with almost all patients suffering from disease progression. In particular, a subset of patients experiences a histological transformation (tFL) to a more aggressive form of lymphoma (typically DLBCL) that leads to inferior survival [26] .
Despite DLBCL and FL being distinct disease entities, these lymphomas share gene mutations that are associated with relapse/refractory and transformed disease and can be grouped into recurrent molecular themes ( Figure 2) .
One of the most recurrent molecular events in both rrDLBCL and tFL involves the inactivation of TP53. In a study assessing the prognostic value of TP53 mutations in 506 de novo DLBCL patients treated with R-CHOP, patients with TP53 mutations had a worse progression-free survival [27] . Two additional studies showed enrichment of TP53 mutations Relapse/refractory genomics in B-cell lymphomas 601 in biopsies of rrDLBCL patients compared with those of treatment-responsive patients [28] and an unselected cohort of patients [28, 29] . These results suggest that TP53 mutations may confer resistance to R-CHOP therapy. Moreover, two studies with matched primary/relapse DLBCL specimens reported the acquisition of a TP53 mutation at relapse [29, 30] , with deep-sequencing analysis demonstrating the existence of the mutation at a minor prevalence in in the primary specimen [29] . These results suggest that clones harboring TP53 mutations may be selected for. TP53 somatic single nucleotide variants (sSNVs) have been reported to be uncommon in FL specimens (5%) but frequent in tFL specimens (25-30%) [31] [32] [33] [34] [35] . In analyses that included serial biopsies, TP53 mutations that were present in the transformed specimen were often absent or below detection limits in the FL specimen, indicating the outgrowth of mutation-harboring clones during the process of histological transformation [31, 32, 34, 36] . Furthermore, bi-allelic mutations in TP53 can occur through copy-neutral loss-of-heterozygosity (CN-LOH) [37] or deletions [34] . In contrast to DLBCL, where the presence of TP53 mutations at diagnosis has been clearly associated with relapse/refractory disease, the association of TP53 mutations to FL transformation remains incompletely characterized [38] .
Another common molecular theme in rrDLBCL and tFL is the acquisition of mutations in the genes B2M and CD58, suggesting that escape from immune surveillance is important for enabling disease progression. B2M is an indispensable component of the class I major histocompatibility complex that is required for effective antigen presentation, whereas CD58 is a cell adhesion molecule that facilitates T-cell and natural killer cell activation. Loss-of-function mutations of both B2M and CD58 have been associated with an impaired anti-tumor immune response across multiple lymphoma subtypes [39] [40] [41] . Jiang et al [42] reported in five of seven patients, missense, frameshifting, and broad deletion alterations in either one of these genes that were acquired at the time of relapse in rrDLBCL. Deep-sequencing analysis of a single patient revealed a frameshift mutation in B2M that was subclonal [0.04% variant allelic fraction (VAF)] in the primary tumor, but was much more prevalent in the relapse tumor (53% VAF). In another study with matched primary/relapse DLBCL specimens [30] treated with R-CHOP therapy, the emergence of a clone harboring a B2M mutation was also observed. Similar to reports in rrDLBCL, acquired inactivating mutations, between FL and tFL, in B2M [34] and CD58 [34, 35] have been reported. Cases with B2M mutations demonstrated depletion of CD8 + T cells in the tumor microenvironment (TME), supporting the immune-inactivating effects of these mutations [35] .
Recurrent mutations in epigenetic regulators have been established as drivers of lymphomagenesis. Currently, an emerging molecular theme that is common between rrDLBCL and tFL is acquisition of mutations in these genes. For instance, in one rrDLBCL study [43] , the two most frequent relapse-specific alterations were in the genes KMT2D and MEF2B. In two studies [29, 42] , additionally acquired EZH2 mutations appeared in the relapse tumor compared with the primary tumors. Similarly, variants in KMT2D and CREBBP were found in the transformed samples that were distinct from those in the FL specimens [44] . EZH2 mutations have also been shown to be enriched in tFL specimens [35] . While the predominance and pathogenic role of these mutations have been determined in primary disease, future studies are required to determine the mechanisms by which these mutations in specific epigenetic modifiers might contribute to treatment resistance and relapse.
Finally, deletion and inactivation of CDKN2A/B is a recurrent molecular event in both rrDLBCL and tFL. This alteration can impinge on multiple biological processes that include p53 signaling and cell cycle regulation [45] . In DLBCL, frequent and focal deletions in CDKN2A/B that are enriched in the activated B-cell subtype of DLBCL (ABC-DLBCL) have been reported in the primary specimens of patients whose primary treatments failed [46] . Several studies have reported on the prognostic potential of these deletions [47, 48] . In contrast to rrDLBCL, CDKN2A/B lesions are generally acquired only during histologic transformation of FL, with reported frequencies of 46.1-73% affecting at least one allele [34, 36, 49, 50] . Pasqualucci et al reported CDKN2A/B lesions to be the most specifically associated tFL alteration in a cohort of 39 patients [34] . Through immunohistochemical (IHC) staining of the p16 protein (encoded by CDKN2A), the authors showed complete loss of expression in cases with bi-allelic deletions. Additionally, a significant proportion of mono-allelically deleted and wild-type cases also had complete loss of expression, a finding that may be explained by promoter hypermethylation as shown in earlier studies [49, 50] . Bi-allelic CDKN2A/B lesions are only found in post-transformation samples, suggesting that complete inactivation of CDKN2A/B plays a very specific role in histological transformation.
Alterations that are specifically associated with relapse/refractory DLBCL In addition to sharing recurrent gene mutations that underlie functional processes with tFL, there are additional molecular themes that have been exclusively reported in rrDLBCL.
Examples of this include mutations acquired in JAK/STAT pathway members. Morin et al [30] reported recurrent hotspot missense mutations in STAT6 (D419) that were enriched in relapse specimens compared with an unrelated cohort of primary biopsies. Interestingly, these alterations were exclusively altered in the germinal-center B-cell subtype (GCB-DLBCL) (36%) compared with the ABC-DLBCL subtype602 FC Chan et al in primary biopsies but with a more heterogeneous mutation pattern compared with relapse specimens. This finding suggests that hotspot D419 mutations may be selected for during disease progression. However, the prevalence of this hotspot mutation is unclear as one study reported the mutation in only 1 of 47 relapse specimens [51] , and another study reported that none of the six GCB-DLBCL cases had the hotspot mutation [43] . Mutations in SOCS1, a negative regulator of the JAK/STAT signaling pathway, have also been reported exclusively in non-relapsing DLBCL patients, suggesting that these alterations are associated with a favorable outcome [43] .
Mutations in NFKBIE, an inhibitor of NF-κB-mediated transcription, and NFKBIZ, a regulator of NF-κB target genes, have implicated disruption of the NF-κB pathway in rrDLBCL [30] . NFKBIZ sSNVs were reported to be enriched in relapse specimens [30] . Two independent studies found NFKBIE to be the target of an identical frameshift 4-bp deletion in three cases [30, 51] . This same frameshift deletion was also detected in the primary samples of untreated DLBCL patients [30] and in aggressive chronic lymphocytic leukemia [52] .
In one study comparing the primary specimens of 20 relapsing patients with 20 non-relapsing patients, gains in 10p15.3-12.1 containing the potential oncogenes PRKCQ, GATA3, MLLT10, and ABl1 have been reported to be recurrent in primary specimens of relapsed patients and never in non-relapsing patients [43] .
In addition to genetic mutations, one study [53] reported a decrease in intra-tumor methylation heterogeneity (ITMH) between 13 matched primary and relapse specimens, marking ITMH as a potentially novel epigenetic hallmark of disease progression. Importantly, patients with a higher amount of ITMH had a greater chance of relapsing. The transforming growth factor (TGF)-β pathway was among the top pathways enriched for differentially methylated regions of paired primary and relapse specimens.
Alterations that are specifically associated with transformed follicular lymphoma Before the era of HTS, early studies of sequential biopsies predominantly used conventional karyotyping and array comparative genomic hybridization to study genetic differences between FL and tFL specimens [54, 55] . These revealed that tFL specimens had a higher mean number of chromosomal changes indicating genomic instability and copy number (CN) complexity. These studies also highlighted the loci 1p36 and 8q24 as being associated with histological transformation [55] . Additionally, several genes were found more frequently mutated in tFL biopsies, suggesting that these alterations may have a role in transformation. Through subsequent genome-wide next-generation sequencing studies, the importance of these previously reported genes were verified and novel alterations were revealed.
In aggregate, enrichment of lesions in CDKN2A/B (as mentioned above), CCND3, and MYC supports the notion that disrupted cell cycle regulation, proliferation, and apoptosis are major contributors to histological transformation. Support for disruption of cell cycle regulation towards transformation has recently been added by the enrichment of CCND3 mutations in tFL specimens [35, 36] . One study of a large cohort of 159 patients with tFL revealed that CCND3 mutations were more prevalent in transformed specimens [35] . Clonal evolution and digital droplet PCR (ddPCR) analyses revealed that clones that harbored a CCND3 mutation formed the major clone at transformation. These same clones were extremely rare in the FL biopsy, suggesting that they may have been selected for during disease transformation. Dysregulation of MYC through chromosomal translocations, CN gains/amplifications, and sSNVs has also been reported to be enriched in tFL specimens [34, 35, 44, 55, 56] . In one study, IHC analysis demonstrated that an increase in MYC expression may lead to a loss in proliferation control [57] .
The identification of 1p36 loss as a predictor of transformation [58] led to the focus on TNFRSF14 as a critical gene, in this region. sSNVs in TNFRSF14 that are mostly found either hemizygous, due to a deletion of the wild-type allele, or homozygous, due to CN-LOH, are highly recurrent in FL pretreatment biopsies [59, 60] . TNFRSF14 plays a role in immune modulation by activating inflammatory and inhibitory T-cell immune response via signal transduction pathways. Thus, inactivation of this gene might promote immune evasion and disease progression, similar to B2M and CD58. Consistent with this notion, Okosun et al [44] reported a case with a TNFRSF14 SNV in the dominant relapse clone that was distinct from another TNFRSF14 SNV in the FL sample, suggesting tumoral dependency on this mechanism during progression following a pattern of convergent evolution.
Mutations in EBF1 [44] , a transcription factor regulating B-cell development, have also been reported to be recurrently acquired and enriched during transformation. Transcriptional activation assays demonstrated that these mutations resulted in a reduction of EBF1 target gene expression (IGLL1 and CD79B), suggesting a pattern of inactivating mutations. The enrichment of these mutations in tFL was confirmed in another study [35] .
A handful of frequent genetic mutations have been described in FL samples of patients whose disease transformed into an aggressive lymphoma. Mutations in FAS were reported to be common in FLs that later transformed but never in unselected FL patients [34] . Additionally, BCL2 mutations [61] , BCL6 translocations [62, 63] , and loss of 6q (target genes include TNFAIP3 and EPHA7) [58, 64] have been associated with increased risk of transformation. These findings suggest that FL tumors that harbor these mutations may have an early aggressive disease component that has a propensity to undergo histological transformation.
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Other B-cell lymphomas For less common B-cell lymphomas, such as mantle cell lymphoma (MCL) and Burkitt lymphoma (BL), efforts to profile the disease in the relapse/refractory setting have been limited in comparison to DLBCL and FL.
One of the first studies profiling primary and relapse/refractory MCL (rrMCL) used a combination of whole-genome/whole-exome and targeted sequencing to investigate differences in genetic profiles between paired primary/relapse specimens in 13 patients (2 discovery and 11 validation). The authors discovered BIRC3 mutations that were acquired at relapse and absent at diagnosis [10] . BIRC3 is a negative regulator of the alternative NF-κB pathway and thus lesions in this gene may lead to constitutive activation of this pathway. Moreover, these mutations might be of clinical relevance given their reported association with ibrutinib resistance [65] . In another study of 13 rrMCL patients, alterations in PPM1D, involved in p53 signaling, were found in two relapse specimens [66] . The relatively low incidence of BL along with high cure rates likely explains the paucity of studies investigating relapse biology. In one multi-time point study of serial biopsies [67] , karyotype profiling was performed highlighting trisomy 21, gains in 1q/7q, and losses in 6q, 11q, 13q, and 17p (implicating the putative driver genes ATM, DLEU1, TP53, and HIC1) as being enriched in rrBL cases.
Evolutionary dynamics underlying disease progression
Several studies [10, 12, 35] have reported an increase in mutation burden between primary and relapse specimens. However, mutation burden is not sufficient to describe the intricacies of clonal dynamics between primary and relapse samples. A deeper understanding of clonal complexity and dynamics is vital as cancer develops through an evolutionary process [68] , whereby genetically similar lymphoma cells (clones) are known to evolve under the rules of Darwinian selection. Several key genomic evolutionary trends have been observed during disease progression. This section includes a summary of the key evolutionary patterns that have been observed during the progression to a more aggressive disease.
Early versus late divergence of the progressive clone
A consequence of clonal evolution during disease progression is that the progressed lymphoma has diverged in genomic composition from the ancestral clone that was observed at initial diagnosis. This divergence can be classified as 'early' or 'late', depending on when in the progression of the lymphoma the divergence process occurred. When comparing relapse samples with primary samples, a high degree of genetic similarity between the relapse tumor and the primary tumor (i.e. many shared mutations, and few unique mutations) would indicate that the relapse clone diverged late from the primary clone ( Figure 3A) . Likewise, a low degree of genetic similarity between the relapse tumor and the primary tumor (i.e. many unique mutations) would indicate that the relapse clone has diverged early from the primary clone.
Several studies of paired primary/relapse specimens (e.g. in DLBCL, tFL) have shown that the disease course can progress through either mode of evolution [29, 34, [42] [43] [44] , and it is unclear which mode is more common. A caveat of some of these studies is related to the small genomic target space that was interrogated: a lack of comprehensive profiling may have led to the conclusion that the genomes displayed a high degree of similarity between samples, when divergent genomic loci were never interrogated. For instance, Aukema et al [67] performed a karyotyping study and reported that BL progression arises predominantly through late divergence; but more comprehensive mutational profiling, not limited to specific genomic loci, may reveal different patterns of disease progression.
Moreover, many studies have determined the timing of divergence based on genetic similarity of bulk mutational profiles from samples, but have not performed more detailed clonal composition analyses to accurately measure the clonal relationship between samples. In particular, solely considering the presence of mutations cannot definitively indicate that the relapse lineage may have arisen from a pre-existing lineage within the primary sample [69] . Thus, relating the concept of divergence to the pre-existence of the major relapse clone at the time of diagnosis becomes challenging.
Progression through expansion of rare clones versus persistence of dominant clones in primary samples
Analysis of clonal dynamics between primary and relapse samples enables the tracing of a phylogenetic lineage that gives rise to relapse disease and its abundance to be quantified at the time of diagnosis. Ascertainment of the tumor's constituent clones is accomplished through allelic measurements of somatic mutations in bulk samples with the assumption that VAFs correspond to clonal population abundance. With precise VAFs, along with tumor content estimates and CN data, computational methods can then be applied to determine the clonal composition and infer the phylogenetic topology of the tumor.
It was first demonstrated in solid and other hematologic malignancies [70] [71] [72] [73] that the founding clone of the relapse specimen can be detected at a minor prevalence at the time of initial diagnosis ( Figure 3B ). In the context of lymphoma, several studies have observed similar patterns in DLBCL and FL [29, 35, 42] . In a study of 15 tFL patients, the majority of patients (87%)Relapse/refractory genomics in B-cell lymphomas 605 present in the primary specimens. Using ddPCR, the abundance of these clones was confirmed to be less than 1% of total cells in the primary biopsies, but nevertheless was clearly detectable above background levels, indicating that these aggressive clones were already present at primary diagnosis. This is contrasted with another mode of evolution that has been observed in progressive FL, where the treatment resistance properties of a tumor are already present in dominant clones of the primary specimens. In this scenario, the imposition of therapy has little effect on the clonal composition of the tumor. It was shown that the majority of progressed FL tumors (67%) exhibited little clonal dynamics between primary and relapse specimens, and the dominant clones at initial diagnosis were the same ones that were dominant at relapse [35] . These results suggest that if the dominant clone was targetable at initial diagnosis, therapeutic intervention might be able to stop the outgrowth of this aggressive lineage and prevent disease progression.
A caveat of determining mutations with very low VAFs in sequencing analysis is that they cannot be consistently detected even with very sensitive techniques such as ddPCR. This may be due to spatial heterogeneity within the tumor, where the potentially targetable mutations may exist only in parts of the tumor that were not profiled, thus making the prediction of relapse from sequence profiles extremely difficult.
Convergent evolution within a single tumor
In the pathogenesis of cancer, it is postulated that certain genetic alterations confer upon the cell a selective growth advantage. These alterations are highly selected for during cancer progression, and consequently have the propensity to occur independently in distinct subclones of the same tumor. This reflects the principles of convergent evolution and potentially indicates addiction of a tumor to a given functional pathway. In the context of lymphoma, studies performing serial sampling have revealed alterations that are recurrently subject to convergent evolution. For instance, a study of ten paired FL and tFL specimens revealed mutations in KMT2D, TNFRSF14, and CREBBP which were distinct and private to either the pre-transformed or post-transformed specimen [44] . This finding suggested that different clones independently acquired these mutations following divergence from a common ancestral clone. Similar patterns have been reported for RRAGC [74] and EZH2 [35, 75] in various B-cell lymphomas.
Since strong selective pressures lead to the same genes and pathways being recurrently altered in multiple clones, target gene mutations may also lead to polyclonal drug resistance. This resistance pattern was observed in DLBCL patients with progressive disease who received ibrutinib, an inhibitor of Bruton's tyrosine kinase blocking B-cell receptor (BCR) signaling. Specifically, emergent resistance was attributable to two adjacent mutations that encoded an identical amino acid substitution (C481S). These mutations were never found in the same ctDNA molecule, thus demonstrating parallel evolution of two independent treatment-resistant clones.
Tumor microenvironment dynamics
In classical Hodgkin lymphoma (CHL), the tumorigenic cells [Hodgkin and Reed-Sternberg (HRS) cells] only comprise 1% of the tumor mass [76] . This has led to the hypothesis that the cells surrounding the HRS cells must play an important role in driving lymphomagenesis [77] . As such, recent investigations expanded the focus to dynamic interrogation of the TME [78] . As it has been shown that tumor genomic alterations can potentially influence the composition of its microenvironment, dynamic changes in the TME composition between primary and relapse sample might be underpinned by clonal evolution in the malignant cell population [79] . Specifically, a recent study [78] profiled and compared the TME composition between paired primary and relapse biopsies from 71 CHL samples. CHL is characterized by the predominance of reactive immune cells in the TME that typically comprise 95-99% of cells found in tumors. The authors demonstrated that nearly one quarter of cases had significantly different TME compositions in paired biopsies, suggesting a high degree of TME dynamics following polychemotherapy with ABVD. The most striking change was represented by an inverse correlation of relative changes in macrophage and B-cell content. Specifically, macrophage content increased while B-cells decreased between primary and relapse biopsies in the majority of cases.
In FL, immunohistochemical efforts have identified the presence of an immune microenvironment consisting of various T-cell subsets, follicular dendritic cells, macrophages, microvasculature, and mast cells in primary FL specimens [13] . Gene expression and immunohistochemical signatures of the TME in primary samples have also been associated with disease progression and treatment outcomes. However, while efforts have characterized the TME landscape of primary FL, work on characterizing the TME of relapsed FL presents an important avenue for future research [80] .
With the emergence of immunotherapy such as checkpoint inhibitor therapy [81] , it will be critical to understand the role of the TME in disease progression and treatment failure. A recent study showing lymphoma-specific immunogenic neo-antigens also raises the question of how specific immune responses may correlate with efficacy of modern immunotherapies [82] .
Perspectives on emerging precision medicine methodologies and concepts in the management of disease progression
Circulating tumor DNA (ctDNA) 606 FC Chan et al translating them into biomarker assays with clinical utility remains a significant challenge, due to the relative unavailability of biopsies obtained from relapse/refractory disease. While currently most measurements are typically obtained from invasive tumor biopsies, a less invasive profiling strategy involves the screening of ctDNA in the plasma or serum of lymphoma patients for tumor-associated mutations. The presence of ctDNA has been detected in cancer patients for decades [83] , but it is with the advent of HTS that measurements of ctDNA could be incorporated into routine clinical practice workflows. Applications of ctDNA include tumor genotyping, molecular subtyping, real-time disease surveillance, and early relapse detection [84] [85] [86] [87] [88] . In the context of managing disease progression in lymphoma, disease surveillance and early relapse detection can be achieved through serial non-invasive profiling of ctDNA. DLBCL arises from mature B cells harboring a natural clonality marker in the form of VDJ (or VJ) junctions, resulting in all tumor cells sharing a common clonotypic sequence. Two different studies [84, 85] have leveraged VDJ rearrangements for ctDNA profiling. In particular, using a technique called IgHTS, applied to a series of plasma/serum samples, the authors were able to show that lymphoma-specific VDJ rearrangements in ctDNA were detectable 3 to 3.5 months earlier than the clinical relapse.
Another advantage of ctDNA profiling is its potential to measure multiple clones from different tumor sites, and therefore provide a more reliable estimate of spatial heterogeneity than measurements from single biopsies. Several studies have been crucial in dispelling the widely accepted notion that spatial heterogeneity is less prevalent in B-cell lymphomas as they are cancers derived from lymphocytes that are naturally disseminated throughout the body [10, 42, 53] . There is now increasing evidence that spatial heterogeneity is more pervasive than previously thought and that a single tumor biopsy inaccurately portrays the full extent of intra-tumor heterogeneity. For instance, Scherer et al discovered that mutations found in a tFL specimen were also found in the ctDNA but were absent from the initial FL specimen [87] . While ctDNA sequencing holds great promise, further validation in larger patient cohorts and prospective implementation are needed to move this technology into clinical use.
Biomarkers at the time point of relapse/refractory disease As discussed in this review, the biology of lymphomas associated with relapsed/refractory disease can be significantly distinct from that at initial diagnosis [10, 30, 34, 35, 42, 44, 78] . These observed disease dynamics have major implications for biomarker assay development and highlight the need for accurate profiling of biology at disease progression. With the emergence of relapse-specific biomarkers, ascertainment of biopsies and/or peripheral blood at relapse, as well as alongside and after secondary treatments, might become a higher priority.
For example, a recent study in CHL demonstrated that biopsies obtained at relapse, compared with biopsies at initial diagnosis, were superior in predicting second-line treatment response [78] . Based on the gene expression measurements in relapse specimens, reflecting the cellular composition of the TME in CHL, the authors developed and validated a novel, clinically applicable prognostic assay (RHL30) on a digital gene expression platform, which identifies a subset of patients at high risk of treatment failure following salvage therapy and autologous stem cell transplantation (aSCT). The RHL30 assay, which is specifically designed for use in relapse biopsies, identifies a high-risk group of patients with significantly inferior post-aSCT failure-free survival (FFS) compared with the low-risk group (5-year post-aSCT-FFS: 23.8% versus 77.5%) and also inferior post-aSCT overall survival (OS) (5-year post-aSCT-OS: 28.7% versus 85.4%). The prognostic power of RHL30 was reproduced in two independent validation cohorts of relapse specimens, in which highly significant associations of risk groups with both post-aSCT-FFS and post-aSCT-OS were confirmed. RHL30 was statistically independent of all previously described prognostic markers in the validation cohorts, including post-salvage therapy response assessment by PET/CT. Future studies will need to determine the clinical utility of RHL30 in randomized trials.
Although biomarker assay development at relapse or progression time points is still in its infancy, biomarker assays such as RHL30 provide early proof of concept that ascertainment of relapse biopsies and 'relapse genomics' might harbor clinical utility in the future management of lymphoma patients suffering from relapse/refractory disease.
Conclusions
Our review highlights the importance of shifting the focus from solely studying primary specimens to characterizing relapse/refractory biology to uncover evolutionary trajectories of disease progression. Existing studies have demonstrated profound genetic and phenotypic heterogeneity in relapse lymphoma specimens, consistently reporting the lack of a single consensus somatic alteration that can unequivocally predict the emergence or characterize relapse/refractory disease. Many of the reported alterations and pathways, specifically those implicated in rrDLBCL and tFL, have also been found as driver alterations during initial pathogenesis, highlighting the relative lack of specificity of these mutations for disease progression. Further progress in elucidating convergent relapse-associatedRelapse/refractory genomics in B-cell lymphomas 607 regarding the associations of specific mutations with the developmental trajectories of relapsed lymphoma; however, future analyses of matched primary and relapsed data may reveal genetic abnormalities which influence specific relapse and progression routes of lymphomas.
Despite the observed heterogeneity of alterations, several target gene mutations have already emerged as potential biomarkers of relapse disease and include (1) events that can be measured at initial diagnosis for prognostic and predictive purposes of primary treatments, and (2) those which are predominantly present in the relapse samples describing the biology of relapse and aggressive disease with the potential to guide treatment decision making of subsequent therapeutic interventions. Importantly, mutations that are detectable in circulating DNA might be used as biomarkers for monitoring disease after treatment, and may indicate where pre-emptive intervention is required. Moreover, further study of TME dynamics and related biomarkers during disease progression is required to effectively deploy emerging immuno-oncology and precision medicine approaches.
